TABLE 5.
Best overall therapeutic responses to larotinib mesylate.
| Best overall response, n (%) | Dosage (mg) | |||||||
|---|---|---|---|---|---|---|---|---|
| 50 mg (n = 3) | 100 mg (n = 3) | 150 mg (n = 3) | 220 mg (n = 3) | 300 mg (n = 6) | 350 mg (n = 3) | 400 mg (n = 3) | Total (n = 24) | |
| Objective response a | 0 (0) | 0 (0) | 0 (0) | 1 (33.3) | 0 (0) | 1 (33.3) | 0 (0) | 2 (8.3) |
| Disease control b | 2 (66.7) | 2 (66.7) | 2 (66.7) | 3 (100) | 2 (33.3) | 3 (100) | 3 (100) | 17 (70.8) |
| Complete response | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Partial response | 0 (0) | 0 (0) | 0 (0) | 1 (33.3) | 0 (0) | 1 (33.3) | 0 (0) | 2 (8.3) |
| Stable disease | 2 (66.7) | 2 (66.7) | 2 (66.7) | 2 (66.7) | 2 (33.3) | 2 (66.7) | 3 (100) | 15 (62.5) |
| Progressive disease | 1 (33.3) | 1 (33.3) | 1 (33.3) | 0 (0) | 4 (66.7) | 0 (0) | 0 (0) | 7 (29.2) |
| Not evaluated | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
a
: Includes complete response and partial response.
b
: Includes complete response, partial response and stable disease.